

Limited Liability Company

Registered office: AA Tower, Technologiemark 122, 9052 Ghent, Belgium
VAT BE 0707.821.866 Register of Legal Entities Ghent, section Ghent

VOTE BY MAIL FORM

ORDINARY GENERAL MEETING

to be held on Thursday 23 May 2019 at 9:00 a.m.

*This is an unofficial English translation, for information purposes only.
Please only sign and return the original Dutch version.*

This form should be used by holders of securities who want to vote by mail.

The vote by mail form must be signed in writing or electronically. In the event an electronic signature is used, it must be a qualified electronic signature in the sense of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, or an electronic signature that complies with the conditions set out in Article 1322 of the Belgian Civil Code.

The signed and completed form must reach Sequana Medical NV (the "Company") at the latest on the sixth calendar day prior to the ordinary general shareholders' meeting, i.e. on or before Friday 17 May 2019 at the latest. Forms sent to the Company must be sent by mail to:

Sequana Medical NV
Attention: Lies Vanneste
Director Investor Relations
"AA Tower", Technologiemark 122
9052 Ghent
Belgium

or by e-mail to:

IR@sequanamedical.com

Holders of securities who wish to vote by mail must also register for the ordinary general shareholders' meeting, as described in the notice convening the ordinary general shareholders' meeting. Holders of dematerialised securities must attach to the present form a certificate issued by the applicable settlement institution for the securities concerned, or by a certified account holder, confirming the number of securities that have been registered in their name on the registration date (i.e. Thursday 9 May 2019, at midnight (12:00 a.m., Belgian time)) with which they want to participate to the ordinary general shareholders' meeting.

In case of amendments to the agenda or if new draft resolutions are tabled, the Company will publish an amended agenda with, as the case may be, additional agenda items and additional draft resolutions. This will be done no later than on the fifteenth calendar day prior to the ordinary general shareholders' meeting, i.e. on or before Wednesday 8 May 2019 at the latest. At that time, the Company will also make available amended forms for vote by mail. Votes by mail that reach the Company prior to the publication of an amended

agenda remain valid for the agenda items to which the votes by mail apply, subject, however, to applicable law and the further clarifications set out in this form. In accordance with the Belgian Companies Code, a vote via vote by mail for an agenda item in relation to which a new proposed resolution has been submitted by one or more shareholders holding at least 3% of the share capital, is invalid.

The undersigned (the "Undersigned"):

First Name:

Family Name:

Address:

or

Corporate name:

Corporate form:

Registered office:

Represented by (first name, family name and capacity):

owner of the following number of shares issued by the limited liability company, Sequana Medical, with its registered office at "AA Tower", Technologiepark 122, 9052 Ghent, Belgium:

Number of shares
Form of the above mentioned shares <i>(please tick the appropriate box):</i> <input type="checkbox"/> Registered <input type="checkbox"/> Dematerialised	

Hereby irrevocably votes, as indicated hereafter in the appropriate boxes, on the items of the following agenda:

AGENDA

Agenda and proposed resolutions: The agenda and the proposed resolutions of the ordinary general shareholders' meeting of the Company, which, as the case may be, can be amended at the meeting on behalf of the Board of Directors, are as follows:

1. Reports on the statutory financial statements

Submission of, and discussion on, the annual report of the Board of Directors and the report of the Statutory Auditor on the statutory financial statements for the financial year ended on 31 December 2018.

2. Approval of the statutory financial statements

Approval of the statutory financial statements for the financial year ended on 31 December 2018, and of the proposed allocation of the result.

Proposed resolution: The general shareholders' meeting approves the statutory financial statements for the financial year ended on 31 December 2018, as well as the allocation of the result as proposed by the Board of Directors.

Voting instruction:

<input type="checkbox"/> I AGREE	<input type="checkbox"/> I DO NOT AGREE	<input type="checkbox"/> ABSTENTION
----------------------------------	---	-------------------------------------

3. Consolidated financial statements

Submission of the consolidated financial statements for the financial year ended on 31 December 2018.

4. Reports on the consolidated financial statements

Submission of, and discussion on, the annual report of the Board of Directors and the report of the Statutory Auditor on the consolidated financial statements for the financial year ended on 31 December 2018.

5. Discharge from liability of the Directors

Proposed resolution: The general shareholders' meeting grants discharge from liability to each of the Directors who was in office during the previous financial year, for the performance of his or her mandate during that financial year.

<input type="checkbox"/> I AGREE	<input type="checkbox"/> I DO NOT AGREE	<input type="checkbox"/> ABSTENTION
----------------------------------	---	-------------------------------------

6. Discharge from liability of the Statutory Auditor

Proposed resolution: The general shareholders' meeting grants discharge from liability to the Statutory Auditor which was in office during the previous financial year, for the performance of its mandate during that financial year.

<input type="checkbox"/> I AGREE	<input type="checkbox"/> I DO NOT AGREE	<input type="checkbox"/> ABSTENTION
----------------------------------	---	-------------------------------------

7. Remuneration report

Submission of, discussion on and approval of the remuneration report prepared by the Remuneration and Nomination Committee, and included in the annual report of the Board of Directors for the financial year ended on 31 December 2018.

Proposed resolution: The general shareholders' meeting approves the remuneration report included in the annual report of the Board of Directors for the financial year ended on 31 December 2018.

<input type="checkbox"/> I AGREE	<input type="checkbox"/> I DO NOT AGREE	<input type="checkbox"/> ABSTENTION
----------------------------------	---	-------------------------------------

8. Appointment of Mr. Jason Hannon as independent non-executive director

Taking into account the advice of the Remuneration and Nomination Committee, the Board of Directors recommends to appoint Mr. Jason Hannon as an independent non-executive director within the meaning of Article 526ter of the Belgian Company Code and provision 2.3 of the Belgian Corporate Governance Code. Mr. Hannon has extensive experience in the medical devices industry and is currently also Chief Executive Officer at Mainstay Medical International plc, a global medical device company focused on the development and commercialisation of an innovative implantable neurostimulation system designed to treat chronic low back pain. Mr. Hannon previously served as President and Chief Operating Officer of NuVasive (NASDAQ:NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions. He helped grow NuVasive from a small U.S.-centric business with a handful of products into the third largest spine company in the world. During his 12 years at NuVasive, Mr. Hannon led the international business, was responsible for business development and strategy, and also served as general counsel. During his tenure, the NuVasive's commercial presence was expanded globally to more than 40 countries, revenue grew from \$61 million to almost \$1 billion, and the product portfolio expanded to over 100 products. Mr. Hannon has a JD degree from Stanford University Law School and a BA degree from the University of California, Berkeley.

Proposed resolution: The ordinary general shareholders' meeting resolves to appoint Mr. Jason Hannon as independent non-executive director of the Company within the meaning of Article 526ter of the Belgian Companies Code and provision 2.3 of the Belgian Corporate Governance Code, for a term of three years, until the closing of the ordinary general shareholders' meeting to be held in 2022, which will have decided upon the financial statements for the financial year ended on 31 December 2021. The information known to the Company and the information provided by Mr. Jason Hannon show that Mr. Jason Hannon complies with the applicable independence requirements. Mr. Jason Hannon's mandate will be remunerated as set out with respect to non-executive directors in the remuneration report included in the annual report of the Board of Directors for the financial year ended 31 December 2018.

<input type="checkbox"/> I AGREE	<input type="checkbox"/> I DO NOT AGREE	<input type="checkbox"/> ABSTENTION
----------------------------------	---	-------------------------------------

9. Determination of the remuneration of the Chairman of the Board of Directors

Proposed resolution: The general shareholders' meeting decides to increase the fixed annual remuneration of the Chairman of the Board of Directors from forty thousand euros (EUR 40,000) to sixty thousand euros (EUR 60,000).

<input type="checkbox"/> I AGREE	<input type="checkbox"/> I DO NOT AGREE	<input type="checkbox"/> ABSTENTION
----------------------------------	---	-------------------------------------

* * *

The aforementioned votes apply to the ordinary general shareholders' meeting that will be held on Thursday 23 May 2019. In case the aforementioned ordinary general meeting would be postponed or suspended, the aforementioned votes will also apply to the general meeting that would be held having the same agenda, as relevant: ¹

Yes

No

¹ Please tick the appropriate box. In the absence of an instruction, or if, for whatever reason, there is a lack of clarity with regard to the instruction given, the Undersigned shall be deemed to have selected "Yes". Please note that in order to apply for such subsequent meeting, holders of securities must again register for such meeting.

In case of amendments during the meeting to a proposed resolution or in case of a new proposed resolution during the meeting: ²

- the Undersigned votes for the amended or new resolution
- the Undersigned votes against the amended or new resolution
- the Undersigned abstains from the vote on the amended or new resolution
- the following person is appointed as special proxy holder, with power of substitution, to vote in the name of the Undersigned on the amended or new resolution: Mr./Mrs.
.....³

² Please complete as appropriate. An absence of instruction shall be tantamount to an instruction to vote for the amended proposed resolution or new proposed resolution.

³ In case the CEO of the Company is appointed as special proxy holder, he will in such event vote on the amended proposed resolutions or new proposed resolutions in the manner as will be supported or recommended by the Board of Directors. Please note that the CEO of the Company is a director and a member of the executive committee of Sequana Medical NV and therefore has a potential conflict of interest as provided for in Article 547bis, §4 of the Belgian Companies Code.

The present voting letter shall also serve as notification within the meaning of Article 536, §2, par. 3 of the Belgian Companies Code with respect to the ordinary general shareholders' meeting of the Company to be held on Thursday 23 May 2019.

Done at, on
.....2019

Signature.....